Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LOUDyBWB4h+gP/a5pN21JIoOXj8+Vp+lO6oro6k3hkctMC6WL6hFt5FYThGiZln5 hzPpvDlW5lWfj8fsvYW5LQ== 0001193125-08-012354.txt : 20080125 0001193125-08-012354.hdr.sgml : 20080125 20080125160026 ACCESSION NUMBER: 0001193125-08-012354 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20080125 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080125 DATE AS OF CHANGE: 20080125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US Oncology Holdings, Inc. CENTRAL INDEX KEY: 0001333191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 200873619 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-126922 FILM NUMBER: 08551019 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: (832) 601-8766 MAIL ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 08551020 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (date of earliest event reported) – January 25, 2008

US Oncology Holdings, Inc.

US Oncology, Inc.

(Exact name of registrant as specified in its charter)


Delaware	333-126922	20-0873619
Delaware	0-26190	84-1213501
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

16825 Northchase Drive, Suite 1300

Houston, Texas 77060

(Address of principal executive offices including zip code)

(832) 601-8766

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 25, 2008, US Oncology Holdings, Inc announced that, effective February 1, 2008, the Boards of Directors of each of US Oncology and US Oncology Holdings, Inc. (the “Companies”) appointed Bruce D. Broussard, 45, as Chief Executive Officer. Mr. Broussard has been at US Oncology since August 2000, serving as President of the Companies since November 2005. Prior to that time he served as Chief Financial Officer and Treasurer from August 2000 until July 2006, and as Executive Vice President of Pharmaceutical Services since September 2003 until November 2005. Mr. Broussard was also elected as a member of the Board of Directors of each of the Companies effective February 1, 2008. Mr. Broussard serves as a director and compensation committee Governance and Nominating Committee member of US Physical Therapy, Inc.

In connection with his appointment as CEO, Mr. Broussard’s annual salary will increase to $899,000. He is eligible for an annual bonus, with a target bonus of 100% of his annual salary, based upon the financial results of the Companies.

Effective February 1, 2008, R. Dale Ross will step down as Chief Executive Officer of the Companies, but will continue as Chairman of the Board of Directors of each of the Companies.

A press release regarding Mr. Broussard’s appointment is attached as an exhibit to this Current Report on Form 8-K.

ITEM 9.01.

Financial Statements and Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:


Exhibit No.		Exhibit
99.1		Press Release dated January 25, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 25, 2008


US ONCOLOGY HOLDINGS, INC.

By:		/s/ Phillip H. Watts
Name:		Phillip H. Watts
Title:		Vice President - General Counsel

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO


				Contact
				Kimberly Rutherford
				(832) 601-6193
				Kimberly.Rutherford@usoncology.com

US Oncology Announces Realignment of Executive Team

HOUSTON, January 25, 2008 — Today, the Board of Directors of US Oncology Holdings, Inc. and its wholly owned subsidiary US Oncology, Inc. (collectively, “US Oncology” or the “Company”) announced that, effective February 1, 2008, Dale Ross will transition out of his role as Chief Executive Officer (CEO) and will continue as the Executive Chairman of the Company. At that time, Bruce D. Broussard will become the Company’s President and CEO. The CEO transition is a planned succession that follows Broussard’s promotion to President in November 2005. Broussard was also elected to the Company’s Board of Directors, effective February 1.

“For the past seven years, Bruce and I have worked together to build and strengthen our network and deliver value to our stakeholders,” said Ross. “We will continue to fulfill the network mission to increase access to and advance the delivery of high-quality cancer care in America, with Bruce leading the day-to-day operations. It has been gratifying for me to work with Bruce and watch him grow into an exceptional leader and manager. His passion for execution, coupled with his vision and strategic prowess, will prove invaluable in these challenging, but opportune, times.”

“It has been remarkable to be part of Dale’s team at US Oncology. I feel fortunate to have learned from a CEO whom I, along with leaders throughout our network, greatly admire. I look forward to continuing our working relationship as he becomes Executive Chairman and we continue to develop our network and deliver on our commitment to excellence,” said Broussard.

Ross has served as US Oncology’s CEO and a member of the board of directors since the Company’s inception in 1992. In his role as Executive Chairman, Ross will remain actively involved in the business of the Company, but will be relinquishing operational duties. This will allow his full attention to be focused on guiding long-term strategic opportunities for the Company, enhancing engagement with its network of affiliated physicians, and providing leadership to its board of directors. In particular, Ross, along with Vice Chairman Lloyd K. Everson, M.D., will continue to foster and expand engagement of US Oncology network physicians, with a view towards strengthening the network and enhancing the value proposition the Company offers.

“My new role does not represent a diminishment in my dedication to the network,” said Ross. “Instead, without responsibility for operations of the Company, I will be able to sharpen my focus on providing strategic direction to the Company and on strengthening our network of physicians. We remain committed to the core principles that have guided us in the past.”

Broussard joined US Oncology in August 2000 as its Chief Financial Officer, assumed responsibility of the Pharmacy Division in September 2003, and was appointed President in November 2005. During his tenure, he has been instrumental in executing several of the Company’s key strategic and operating initiatives such as the expansion of the pharmacy division, capital and operational management and, most recently, efforts to improve the network’s quality and efficiency through the Practice Quality and Efficiency (PQE) program.

As President and CEO, Broussard will manage the overall performance of the Company, including leading the company to achieve its long-term goals, continuing to develop and enhance its executive team, and establishing and maintaining business relationships with its network of affiliated physicians and other customers.

“As CEO, I will continue the focus on operational excellence and prudent investment, combined with growth of our business through physician affiliations and expansion of services. Delivering value to our stakeholders from these efforts is based on a foundation of strong relationships with our affiliated physicians, combined with the retention and development of talented employees” said Broussard.

“We remain committed to our strong belief that we must drive down healthcare costs, while improving the patient experience. Our commitment is supported through our continued execution of our Cancer Care Management and PQE initiatives and through the expanded implementation of our electronic medical record system. Our Cancer Care Management program continues to develop through the adoption of evidenced based pathways and expansion of patient education and end-of-life planning capabilities.”

“This is an excellent time to transition the CEO job and management of the company to Bruce,” said Ross. “I have been privileged to be CEO of US Oncology for 15 years. I have had the opportunity to work closely with Bruce and have tremendous confidence in his ability, dedication and integrity. He is well prepared for his new role.”

“It’s a strong testament to Dale’s leadership that the board has selected an internal candidate as the CEO successor,” said Russell Carson, a member of the company’s board of directors and general partner of Welsh, Carson, Anderson & Stowe, the Company’s largest stockholder. “The Board is confident Bruce will continue to lead the organization in an innovative and disciplined manner, while furthering its mission to advance the delivery of high-quality cancer care in America.”

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation’s largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.

# # #

GRAPHIC 3 g74455usuncology_001.jpg GRAPHIC begin 644 g74455usuncology_001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`B@"!`P$1``(1`0,1`?_$`,(```$#!0$!```````` M```````'"0H!`@4&"`,$`0$``00#`0``````````````"0(#!P@!!`8%$``` M!@$#`P(#!`4%"@\!```!`@,$!08'`!$((1(),1-!(A11,A4*87&!%C?PL4(C M.#-C)34V5A=79QB1P6)394[3L3O&]C6%[DNS9^H(_)3D%,CCF?-G^,+?X> M.7*_(/`:F.+D]*ZR5@].)K;I\\E#/I6TTIV@H>M6AR1R/U0K(@B+!RH(G`54 M"&W#O+KR?NFXJ3QYR`+Q;VU?]>NX+C:@/*A<_,C#_EC+YC'M?:+RZOD38ILE MT6E-^M)#:AU6W*0,CV2(Z](=^)_2Z;#W#N&PAUV#?D*@**NI1^JF!@(!Q21[CCT*.O2[1VC==\;FI-L69!<>><'J*"20A`(UG# M(@9$]981X/D7?-IX\VG6;INRPAIE'Z229%;A!T`]J2?F`EAUB!7E_*-QSADV MY99R"_\`Q"W7B8$/(V0XL\D\;Y3;K)HP"4D%:O2*[A\@Q<4JRJIL)IS(I,"++ M/"0@JE?I$]LP%5;E]"AT\1SULA'(?%E;8@R%W-O]6G4D>=*DC5I23.041(]Q M.,>]X)Y$?X[Y0I+TV[HMRG4M/),]*FR9$D`C&1./W1/3B9%E,1S.5C7;=]'2 M3=!_'O&IR*M7;!XD1=FZ;*IB)%4'+=0JA3`(@(&]=0I+5])4N4%6E2*AA10N M8D=:209S^R)TJ:J%72-W"D4':-\!:",?(H"4OOC(]=_L_1]OV"`ZX96IQ*E& M6D'".^M"PH*21Z4L>V<5U=CB#2$&D(-(0:0@TA!I"#2$&D(-(0:0C$SL]$5F M(E9Z>?MXN&A(UY,2LD[4*DUCXR.;K.W[YRH80[&[1J@=0X_`I1U73LU515MT MU,CU'GEI0A(S*R92`^(CKUE534%$[<:Q?ITE.@K<5T"4B9B$WY)>=+KF7EEJ MWJ3B5881QZ#IE1(=XJBG''*&XQZ[]?7UUL8IQUUI9<`]=7V2\8U:7B@-)2`B^+!:47$KF1Y<2,YQ*E\*/,[_2'0'/%>^S M)UKIBN-5D\=O7[C=S8,;%.1,\04QQW6=4MRL"12AN/T"J7_-F'47/NWX@9VC M=QO.T-__``->!ZI'_EU()U$@#RH4DHDK(D'OB6[V<$ ML%#A<"II[.^*ZOQS!I"#2$&D(-(0:0@TA!I"#2$&D(J`;_L#?2$,F^:SE-*X MAP9$X=I4L6-M.;5'L3.+E9_5+M\?M$A)8FJ:P#VQ[B;.ND@4YRF$Z`J@0-^H M;7^TCC1C>>_E;BN@"K7:$AQ*3U>Q*>X@!./PC3;WE\J/[+V$-K6Q6BY76:5J M!D0S(`R\9G[(B-%(4J0`7KVFW,(@`C_P`([!\`U*RPA)H_4 M1_="OU.[HC\8A\*R7SJGZ9^0]O57X0:IB[!I"%.PMF6ZTV!O2Z<>;JI-VVI9%53.@A&,EB8UI/PD/C* M)Z'&WD#1^3>(*CF"@O"K1%G8@+R.-O\`75V?:II$G*Y*$'84G\,^$R1AV`JA M`(H7YZC;-]045;*SIPD%-_E6.V8ZC`&8Z1.WQYO:R\A[8I M]S[?7JHW4#U,9Z79#4GX82[C"\:\I'N(-(0:0@TA!I"#2$&D(-(0:0@TA&JV M^V0%)JM@N=HE&\17*O$OIZ;DW1RHMV47&(*.72ZBAS%)\J:0@4!$.\VP`.^K M]#;*R]5;5FH$%RHJW`AH)!)*E$"7VD1\^\7>AL5*]=K@L-T-$TI;JCA@!/\` M`Q`RYF4!]?H]1\X?W5@:Q.0PP$NZ((N;N0G.2^0ZS<0) M^A!])D3)'I(4HI($^U2HY@#<`Z=-@^W[/Y]9/6PY4)*&U^FH>:?ATC$9+8EZ MJ=:3A+QBT3%ZB8Y2^F^XC\=NW?8!^\8=@^T=5TP=^G4\R`I:3F8*9]"H#2YZ M#T&<7#KCQBJ*@`#OUV$`W_GU2%G]5M?]C0#\<9Q:<6IMQM37]W5_"'@?#IR_ M7P)GDF&[;)^UBW.<@QBT0=+C]+6I1U MJ-[KN+:;>NUAORSHG>[4R=8`Q6P)J(*B`"1U0?V,>^NWEA%&6`R@TA!I"#2$&D(-(0:0 M@U2H+(DW+5%*E!(F8/CMTW$-P_9U'5M:UIDA,O5,<)#F*UR#0B-EYI>9THS% M3BS2)BMK-WO8\R,K#RMD;W&OBFTC'<9#2J:!HZ#6C)]E*K%4;B+])1,@"_P!HO$E)=ZH[^W&S4MKIB#2#RAI2L3JD4E2I$#(ISPGTCZ]Y?,]30T/_ M`.>;;>IEM/@BJ4)J=`RD%!0`PGFDQ&U#H'Q_;\/U?RZCJ1EM9N>/CW= MV41AK24'3@4`8'M'?WYQ7O=%I009>I,(!$R,QWP\+XE^!T?R;R'+Y5RQ7%Y#!^/TW<2@Q=D6;L+W>' MK9TS_#4E1(07496F2QG+@R8@`/!1(!N@ZU$]T?-CFR;/3[2VF^EK<;^+A`F6 MD@C$CIJD4B>.9&4;K^TG@YO?=RJ-W;J86YMNG$D3P]0RGA@9RPRZ>,<)0N1<.R0.UXN#E1DJ9+NT!1_'Z/-`#RN2:*@`*+@Z*)S-7`DZ%<-S@( M!Z:S5Q#R10\E;)I=T)EZND-U#:,T.@`&4Y^6>.,8!YGXRK^,>1*G:1!^D)+C M#B_SMDDC'#'X1S0.VP;>O;\WZ_CM]@;:RH'04J;`&D&6,8B;2HJ]1?S`X>$9 MBKIHKS$>LZDR0+!%]'^_8C).79Z\HJZ3%K.(-8Y4CYRZB%B`X1!(IP]U,O<& MVOEWE)2IM4T2^<2,TGN.1C[]EJU4]YIZE;OIK0L:5X^57173$=( MG-<#>0,QG+![-K=GK=]EO%KX<=9358E$6TE.Q+Y8Y1V$H@$*?+&UD;/WD^FA0462L0:BF;5BIL3(6VH@"1"A(#2)"6!*0H`D)4%&6[;;60^*ME73>>\J*WTC275H.I:2H)!`4)B9!F.WQC%G,W(%'Q_LFM MN%8X4.*DEL)&I4U`@8`@C'K$%6Z%M1[))2%X,HXMLX9"R3;Q=TD\7M3-NM+09I:N-T>]>HJ%*))5J,E&8Q[@8U8/37WE(6M9F`)"?=]O;'PDZ``$J)![ M>WL$*+B'%=LSEDZE8DHS95U:+S/L86/`B1E$VB*QRJR$PZV*.T;"L2*.7)@^ MZFD(#U'7AM\[OM^S-J5>YJU>ANE3-(.:UR.A($Q,*(E'L-D;1N6]-U4>V;>V M5NU3H2KN;F`L^(!G$_+!.'JM@/%5)Q+2VB;.O4F`80[82)D35?O$D2FE)IZ) M"E%:0FI$RCE90VYC'/ZZA+W9N>Y;VW%6;HNCA6_6ND_TB9T@#I),A+NGF8GQ MV3M2T;$VI1;3LJ-%%1LIU&6*CU)[22(;K\M7"8_)K"XY(I3`%LO88CI6:AVZ M*11=7"G@4'M@IQEB"1=1P0B!G<<`;]KDIB;?UNLX>V'EY_CC>'^/N"@=JW5: M$.B<_2[2B6Z+2VI:%'REUJ6HI)D9D2,A M\(AME'H"`ZE[46W0'&9%!2#,=>L0Q*) M8=4P],.A1!$LNZ/J9"Q*\:&DDG2T>"R8/DF"B"+]1F(_UR;-=PFHBBN)!^4Q MBB`:ZKYJ"VI%+J]?N&HRZX1V*=RG#R34";0,R"9#[8?$X*\E&>$ZQC#)4EE> M.C6./QC,=7K"48[(_T&*-0IWZ)M6LO4RR"I\R.+K8GI1U,L>R6`U=HO&R+MN83HN$D5D M3=#>XFND55,Y1*)BG*)#>H#L.M`2VM#ZZ56#K2BE4\,1A$G+"T5++=0R4EIU M`4G'H1/'OETCZ0'?[?VAMK@@@R,5D2BNN(X@TA!I"#2$&D(PEEG8FKP$Q99Z M0:Q,%7X]U-3,H]6*@TCHN,1.\?/G*Q_E31:MD3',/KL&KM,S4U54S24:"NH> M=2V$C,E9E(1UZRXTUHHGKG6*"*9AI2U$Y2`G]\0H.?/-28Y7V%*5CJTO!4P' M\A'Q;LKYP[:VA:JSV28C3Y%L8R:B*9OK72RGS&*GV2V>WWB"AX M\M[SE44N7YQ"5IPQ2"D3$^]0)[A(=,8:/<+SG753KIJA( M4RH%"N\'#]QB"7Y`>/SSCMR4NE77;(-6]B<&NC5JU-[K-DE9GSUVV1:+HLF3 M91HJW*"@%3*(I*>X0=NT`"93@7?2=[<=TEQ0HJ6RHL+)G\[823.>>"A$(/N, MXZ.PM_UM(4A*'DA]`&00X5`2^*3'%78!A,41_HB`"``.X[#MT,`^O_#K/I;6 MBF+[9(5+,9R.<:Z-N%+?K%(4`H8'*4=,\3\X1V"LSUB[W'\3E*9#Q-WC9"$) M'L)QJ);K`.(=P/X1*IK-").GQFYG:R9/?!)/H/:`@.'>6]FKWOM%=)9%+3>B MM!US*3Y%A0\R9*PD2!E/`X$QF#B3?-NV=O)N[UK;:[2!)39Q'9D.>(-'-1BO;;-@2G:G$.6:[LN MQ3KF65."9"IG*6)G?-D6V[7W%A"TB@>#-4E2=*D*Q\ZL3@HSTY2PSG$R''>Z M:)AF@L%PV!1[Q'H`=.@B._H`AJW)PK4& MDR=DF2NF9F/&+*TN^LA4YTQF%)[\)&(_OG#Y'.ZU2*;@VJWJ-9KVLLV\R/4& M#PX69Y`O&!V]95D&14S*-ZD\=E7%4PB!55DTR!Z#K<_VB9.'=686)5HZ80P[0( M#HB8E(=;<@"<-2(7+T%4-98:$_\`V!T:TJZ2(('<9$'"<1C6MI>MF[K;+EJ" MQJ']!F?WQE.,=K=^Z5 MW]YIE%,RQZ79AATGE..H/'=QCEN3'(BJLEZZ_E*'2'D5<[RJ,85Y%GCVD@)8 M>*ETEQ*5>,G)5J)%0)N)VR*X;AK&G/O)-MV;Q_4--N%J_P!8%,L)4=*A)/F4 MG(SDKRGM$95]NW%E5OGD.F#K/U%JI2AY[3YD@%7EGGA-)G.)J6.\9,J6X=S3 MQ\M8[;)-$F,A:)%),KT8M'VCM8&+02`$(BNL7!3'0:(@5,O=N;N/N;40USNO M^1<24#2P"J0'^XGS$G,E6$R>LXFIM%CIK3@I7J7`("2J4@E&24`9`8&%6U\V M/N0:0AK/RJ\2B\B\#35IJ59;S&6,PF<)>;KK1Z#B MQ'(O'[]3;V=>X:%!6@@>92`)Z<,3(@D#QB%NZEU#RF7YHJ&U%*T$2Q$ M6>OKJB.)`0Z)PEY,Y(!_CC&$192-;OB=#)`\;(_]S&UA:/)N^P,F_GHB853( M[DSOI"0AF<>S6(`%29OER_>(GK4/FSBRRAJKW*\T44=U<:_RTU2TM,J'IJ3/ MRITA3BE3S(3VQN+P?R[N%?TVSV'`[?+93N)M1(G^LZ#K!.9G)``\8E\8(R?& MYGP_CS*48U7CD+O5XZ<7BG0*_5PTFJG[,S"/15(0Y7D-+H+M5`.!#E,EL8`' M49NX;3_@+[5V(K#BJ1XMZ@9S&"DG#M2I)B63:]^_[/MZDO\`Z?I*JF0I2B6FVU!,P6%$'''SS*_,`,)2B$GEV]N7FYI MNU2&WZEBI)#A=#BES5\K@$II[):93.<<[&GW+Y@_CB@:)B$WDI/*QL2X>),7 M3F368IMH\63I^J@5FQ*T*F0Y2&6*E_=#'[0VR<+8Q2U/UB%+-3Z6C493`$\9 M@#$SGV=@C%@N]4];T6](0W2H*C)`(GJE.S",3+I1J16QH=VH_1=E54!)9 M+V5V9@?.4$6JX%$YE5%T4"F$Q0#Y%-]@U]BFJJUY3-,XVXE6DD:<)GIF#'Q[ MK2T5/6AQEQ*FEMZE3QD<9@8CNSB8=XL&O%#%7%>CR%)R-1C7.\QIIW),O8+# M7(6XGL)'*WUE?>Q[]\C(L("N.#'28MC_`-6"9A6^\J8=1%>XJX M>;#GJ$2*0/*0VF0*09F:B9F>#AD[R&P-5A($[F?&D>L<-DT7EXK93"4K19\8 MQ4TWYC',9HW.H`!U$H=-_CA>BVGO&YKTV^TUCA6[*$))Y(.$ZS$9!OR*QRY2*N+0K5.45:R+EV!NW MVFS.309*J)F'H"@@"?Q[MNNO8,<+2>YZX?884\ MN]TI(.04/X_C&UQG.7BG,K)MHO.V-GBQCHIB'[TPK,AA58)2:BB*TB_:-UT& M+-<@N!3,IP,4.FYQ1R*TG6Y9ZP`$CY%$X&6023CT_".V.9>,3*5YH\ M9?G3U\51\5GYR\0X6JS-OEL_8T-68R41K[?RX&.4YR8M-GXMRD;(XQM$ M-!RRK6#@U:[`0-I*D=G-14,Q6:,3+-EBH).S'!,-E7!PW';4K/MZ8W[0\?IM MF_Z9QJX,*"6UJ)F4=-4^I^Z(A/;-1;FL[UHO0*J:L2Z'`)"8<0$$#`R``FGL))QC[^V[ MW7[5OS%\MNE%71NMN(49DS0K5,XB8)^;M`EA$U3@/R'CLR8[@YYK>(&=B352 M`_'VS5A`5F/JN5)VFNE; MI$*7)4M%0I2]:`,9(D$J`.,RK''!R`HB.VVVW7?;]&WH.L/:@LA3.+ M@\3V1<)0$:4$Y;C;C*3>.FE5O+]K=)1NC&O8&;2A8 MYW$.F)UCO'*BIV<\X%9N9--+L5;@<3"8``)$/:SP9=*.J;WMNJG4BF>I]=+H M(6KS&8*T:9H,QB#B!V8Q&7[MN>V*^A;`*"2#YDRE(]Y$ M,)BV6D2J2+5BX.+0&;625(JJ_75?/3G316<&4W<&8NQC@0I3CZ[@)@#<0U0Y3L>H5@-*4 MHS)4W,S\9Y1?;KZ[TTH;4I+:!I`U*R'@1VQ4$`W^?^L`/@<>\`';M`0`V_4` M'8!^`:LK80)*;;8*P1D@),O&9^SK%Q-;4J!34.+#9!R*CCTPG'V%7RPRE%FN(L1=TVWWZ M_9MTU6M9+*=']Y,7E.EQPZ\&B/C';W!+/>,\%95=RF8W60UL>/F#)Z6!I;E0 M[`;Q"RL<[K-FE(;WVZ3N1KR*:ZD>X*8JC5R!!$1)N4<`<\\;7O?M@IVMI4]& MN^)<6%EU*4G0L)$DNG($CS"67B(V%]O')>WN.]P.U>\*BK19U(>IKQ22<6 MQCU$LF9.8]TVD8Q<6\C&23!TFFX8 MR#)8-E$S@&VX"&X&`1B1W;M.^;'W*_MG<+/I71A1*])U(Q&&E0P4#+I$T&S- MY6+?NWZ;L^0/*701H;)/\`NE.6>!C5WW3.`.NH[D))XNQ.4^1$N6]JN9L>W'B`M1FJH*>J22 M4)`4#(@`^(G&=]B[UXOXWJFJM-N?OEZ9.L)494X<&*52"%$E!Q&(SA%^2V?K M-R=S):LR6R)CJ[(V1"&9(UR%7>JQ,#$PD2A$L(N,,^$54VI$4C*"4H$3$ZIC M`4.X0UDCC+CVW<;;;;VK1U!=I6E%2W5`!3RU?,K#M^/B8QORKO\`N/(>\5;H MJVTTU8Z`$M)P2TD'`#]AE"!Z]T<\,HQ@<\ M^2+=51U(J([`'Z1`-Q`1`.X0*`[!\P]1]`ZCJF.^,H^APU7:*%2<"@)SHMW! M?8<(N2`DY0(NB!E4#'3]WVS@)B[[D'H/4-(Y.!CPW`0'8=_U?K#2+3WR1;JJ M.I!I"/44'((E=@DJ5H+@&8N03$40<*)F4*D=3T[Q(7H'PU9%6FEJT%;H0D]/ M".Y3TZG&E.>D5IR![XDW>";D@\G86[\:)-@Z,C4FG[\UB30(\7C48UZN1K*L M72@)+-FDF]E%AP2Q$I83E$B;6BL2#0:0ALWR*<)8'DKB M*]3M,QO6+)R.+78N*Q]9K!,OHQ6*:1\PD^>L(MT=P>-8'<,5G0)@=,B:JQP% M0=]A#-G"'+5SX]W71NUM>\SM93LW4-(2H+!_W8$_$8_"->N?.&[9R;M&JJZ& MVM5.\$H_3*U$*$@3(=/`2B)W:.%'+VER3J)L?'#+Z+ML)?>4CJ=(3C`Y#_W, M6\A`$DV#E+8.@IJ&#X]-2C6;FKBJ[TIN#%]H:="UGRN5+;2\AB4*\P[.F(RB M)F\\%I80"2W3NN)Q)_,F0^'\8TQ?C1R*;E_K\#Y<2_P`%'F^U M2@60HA&)F4*HN;>-`"*%%(?ZH1!80VV*.OH/\M<9!`T[@MSA*@)"J:7GUT@C M+QPCY2>&^4\2O;]Q:2`25&F=1\)F>?AC&,B,"9NG9:'A([$62Q?3LC$Q4>+R MCV6-9F>3;]&,C@[>MD)* MB$NH4J21,X!1,P.DIQ\NBXMY!K*H4S%FK@_.4RVO.0]S0OK MIM2WT*QH+V1A';ZP(.V32V6>(6>)NJMC]8C)9.U2ABL3JI&:@9`Z6P^Z`B`: M\M>.>=AVUV@;17H<15D:I$30DB8*P2"@=/,)SPE'KK-P/R#U+!5M-V9MNOI%N:5"9U`C/`"D M9,V-[4]V;DH7%WNI3;'=!/G03@GY53U)S)(EVB%$<^'W+$N-*;I/=WMMPU7^ M5HOIZ=@MA(0J965Z@0F8!\DAJPR(CT5P]G>Z'6J<6FY,UE;5-NE8T%(2&@DB M9UD">K#ME&*#PY\Q[Q./DA0^FJE:/#'S2PF.SS2SEAG'5/LJY(_].4N MTX"C]DY=A_E&J?\`U+W^*`[AJ:XKD0O+,H^:F8T72 M$K+SI8]=%)%@540.!1$^V^NZ[[L]AO\`UOT;;I33Z0WVK*LY),B`G-1,A*0:8TBZH85!5KSD`#\?@,\HQJWC>Y#?C"U-K-6ACPB%66S4JC3J.+Y&`E^7Q$X3R6\>?+Y&7 M3B'6(Y<\N52>8+'3-`-X1$M04:(O`,_:/#H$4!BNBLF95(!G*0)E(:B3_.%>;^)KE`=.L0LXDPC<@V-W(+15=!A-3-3K=$AP?'EK5;K[ M!LWL3$+R+LZ81,<@FL[?"8_RI@`;^5<]V7'C50XY9&E/V1`&IUU24O%1/R-M MD@F0,U*("1WXR]LOVE$/'9RCS;<"UM MKC"Y5*%.YE&1[K;ZY)5RNE>1A05,0B\NW;+"5TAW';B8A05,4"@.XZ]EO/W% M\>;4LI?I;HU<*Y2`0VVI*R-0P!TDY'`GI&/]C>VWD3=]Z3355K>HJ%+A25K2 MI(,C(GS`=D^_I#L:'@/:ROX&_6SE(P+)U&=T]!JU9L[D&$T4SY-)U&/6SUNT M68BW*U$4E414$X*"*H@(`&KR?>W7T=*_3_XIMQY;Y+;A4?DDD`$'&8,\L(VV M5["Z*L=;E>5,-EA(6V$@^<%1)SZ@@=TH<8X1>-RD\++7-VV`LK^W3-BI\/7Y M24DU7#909)HJHM,/F,0B88UHQDEC@*28F55;D`2`;8YM\#\M<\[AY:IFJ*Y- M-LTC+FJ2">GR@SGB)XRD)]T;%\->W^S\/U;U;1UBZE]Y&GS`=!YCA#F9AW$1 M#^736"8V'BW2$<;E\@'!Y2[(8Q)RMP0;)*QDC-\NJ"DZDE"E)2G\HEI/B)?C'(P<4Z/[BAG_"%:S!R)P1Q MUA8BQYTR]0L/UN?>?AT1/Y!LD?5X=_*'33.2/;2DJ=NR^K5]P@(HBLO1'XM M99TU$?#LQN\C"UJ-F)&!J4@;<$)&03:M5Q`0(9!P:)E`48+N2?0R8,5O84W M[#F1.!/F(;1(*3,E1'83A%*DM*_(@*[0!.-/RSE_#F$82,GLMW>L4F/F)EO7 MJZ$^[*1_9K*\!8S2NU2$;(N)>R6%8B)CE9QZ#AT9,IC=@%`PA4E3J3J*UJ/> M=9Q%DAVLJ3O,DJZ8D1FVJ)'.:M?;/&+FE!F"E. M@B4I"7PCP-$QQ_;%1FW.*/<*!C((B=`RFX*G1/V=Z1URB(*"40]P!^;?<=7$ MK=1DM7[?"./39DD:$R0<,(]@8M0!(I4$BE1'N2*5-,"IF';N$A.WL()BAMT` M-@]-MQU2DZ"2C`G/OBI8#F"P"!EW>$7@T0*04RIE`@[B)=@V,8QA.90PB&YE M3''<3#UW#?14U.I>/SIR_AX#I%L-(#:FT^4*[)3GVPD>8L^86X\5E.Z9TRI1 M,0TU5RE'DM>1K,TJM93>G$OMH.9J7.U8,U3F5*0A5E4^\X@!=Q'8224@`XD3 MQ.>,5!`"BK,$2ET^$;5CF_T'+M&K&2\96V!OF/[E'DG:GG3]FJRH&>`!. M<5'$)2?R3E\>V+]4P@TA$$Z9*'_[9(?8I>E$:&'Y0]?]RQR'=Z?>W'U]=(1, M`YK0,)8\".8FPQ,7-QBF6>-ZRS&78-I%F*K?D1BU9!P+=T4R7O-E>TR9_O$, M&X?9I"(G?CJ\X7%/A]SD\L.*?(C8IS#V;\B\^+>!6%LU8SXUU-4YEH2I2T%D*CXIN= M[9LU#.&I+7;GSZ4.L]*`+%:G21*/:D`:0CZ_S)?)RT^-[R`>*7GKBYT$18%3 M98Q/F=F@846N3,'0]DQS+35*M**(?X48),+C)+,3*^X9D\%-9/M.0-T(D/P_ ME3X!S^4YO"$9R'A39BK=*#(-AQBZJE_87:&K"C"!DVBSJ"?U5N]6DI1I:&`L M6*`+/7XNDP;I*"8-(0HO%;GMQ.YJ&R,TXXY:C[S/8?L"M7RI3G\)9*7>L?3: M:[QL#2UTNZQ%?LD2DJXCUR$74;`@91$Y._O*)=(1@E/(YPR2^FD3YJB/W%>9 M2;X/:YC+$3YL&.Q*3B1F.Q'YFX/2B@*H*@)-(0J.2 M>5^#,6Y$B,.S]K>3.8IRJR5[C\24*MV'(62`HD.X3:2=VD*E3XV7E(>JMG:I M42O79$$EUQ]I$5%?DTA#&'YB#.&(N1G@)Y-99P??ZYDS'=@D\/I1=HK3OZIF M=Y&9SI+"4BWB"I$GT1-P[Y$Z#QB[20>-%B"15,A@VTA'3OBCY#87XW^%OQM6 M[->0(6B1%@P+B2EU9)\#Q].7&YV'W64#3Z768AL_L5ML\LZ4`B#&/:N'!@W- MV@0IC`A#H&*>4&$\SVZ^8YI-O,&4,6EAULCXKM$-,TO)=+8V%`'4!,3=*M+& M+G$Z_-MC`9K(I)*L5M^TJO[Q/EL)9\5]+6%M7Y^L*RM9,D2#MN^D(F!\Q':`8@B8D5.Y]:LV\;ZW#-M@(H^DW^?\;+(H(&$=CJ% M9,5G!@VZ)(G'X:0ACW-_B!\8_G2B[YR9LU6LN'^1==R[FC`V3_EZ>&V6?&1Y M5_)IX_'N29')N$Z?A_"^7H"P"@>*C7\E;Y=LK1IJ3KQ'3UE!W%[59.19/BI* M"5P,8!BB9,J?:A"&>$S#=IXG?F8O*?A6\MW,6YNV/;C%#ID%TU6@;`(F%/Y2JI*$,.Z8AI",U^<#Q;9^2&:_$EQEQPP=SN2,LY M&S'68&"8@"SI0;7*89@$)`4$]UTFC$2KK.%C`"2:*)CF'8AA!"+>-%/AFOYQ MS.<"^:I2I:!QAC$(-P^#Z@[61KW&G"5:;2B0J!L#PC%PN4A]@$GNB)=AV$$( M;2NN1\J8IY;_`)L*Z89E)F"NS'&UACDY:O.7365B:Y8N3M%K-WF&2C10BR#I MG2IF1$7)=CMB*'4`Q>HZ0A^7QX>,C!7D]_+V>.#!^:+1D:CUBFV)UF%D^Q3. M-8*0D+%#Y,RA'.(^9(^823!ZRE6/WCN0_#<;T7,CFI4*'B'3XI%@@R5&O,#)]A2$<=% MMA$XF%"&&I6Y9*'B!^:"Q,46<' M@'M^FYS*[*Z39&G=](:?9-JS"I"H&ZR"8)=HE[NJ$.+>2*Z6N@?FE>-#>FW! MY0JWDO@S,TK/EF:NUD(Z'PXYJ'(%Q:+3:#)F(BA&T=M$MIE)180*DZCT3`8I MMATA&$@O%AS0RUXC>%7C4K.-K;7KAC;G:ZS;-\DYIY!5W&:&"$KED>WP.98% MT>PJW5S8[/$6]FLP@C,$IA)Z<0<%1(7W10A>?S7'&BYTW%_$7RD8/.[3S/P3 MRG3HRTVAJ5<7&9_RPO6/FZ]8YG/(/(432;I%MW1F.-*O7XBIT*&?L5R*$]A%["OI5L(#M MWR(K%ZG$=(1VE_N^8'_U,XP_^$P'_<=(1P?Y#/$=QL\B4SB[)ETFM9##7)C!\^SK65J2JRD@F&<>HX?1\E$V"#;2@F<)-W2/E<:Y,KOG#,U[/%FM5XD(2)2KU0@6S&$8QL%5:+0:ZB1 ME"0\>W2;M$0,8PJK*JJG0C4\]<',99HS?B7E-!RD[B'E+A!C*P%%S=1DHA>5 MD*)8D56]CQ?D6NS#-Q!Y"QW+D7.K]$[*1PR=;.&;ANKONA&.I_!&@(\HV/,_ M,MFF<[\C*S25\;XNLUEBH:OTW"5)D%W+R?88HH,*F=C`SMM>/%!E9IVXD)9R MCVH$720`4S(1SS3_``^X3I/D/N/D[B,PYU7Y,WN*>5NS&?O,;*T%_5'<+"UK M]WT:NECU%9DBC!5QDB1R1U]2'L]_=WF,(H1B,'^%GC;@[DMRBY1-;YE?(MPY MGQ-JKW)>G9*+C68QKDJNW)\:2FX(*Y&X_BG<#'.'1OF*V=$,8@;;_$4(4_CA MXTH'BEB-_P`9\+\ALVUWBS^/V:6K6'%EJ@]F*3!W.4=S=FQ[4\O*U\AUX8\:>:VT&RL5HMQ;Z26':IQDPBJBX!!($717*7R@A'/EJ\'W$>R M\+L@\&FVY++:>!ECAK#Q%SV9>G(Y@Q&2$ M5CU4:ZI)Q]390-UJ4J#`I)1A*L5B/B#N)R'(FYW)P%=J4C7\'K5YW71QKBF+AHX(7'L9*/)@7/[E+D>`M?./,_CJ MQ5*9+X^.RRC7(DO<\$( M>YPABR"P=AC$N&*NV1:5W$^-Z7CB&;MTP21(PIE=CJ^B8A0(0!]TK#O$VVYC M&$1ZCI"%1TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA"0\@_X#9J_AG_"F M_P#\:/X0?Y+R?\4/_8'_`(M_V+W-(0P!<_[''#C^T;_E[AC^T]_8I_QK#?Q7 M_P!C/^9']^_#M(1P5RB__K9XT_V;/X,T;_'7\0?\C9C_`!G_`+5?\T_[U])I 9")IR?H;_`*13]?WQ]?\`B_1MI"/32$?_V3\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----